AU2019323697B2 - Acylated calcitonin mimetics - Google Patents

Acylated calcitonin mimetics

Info

Publication number
AU2019323697B2
AU2019323697B2 AU2019323697A AU2019323697A AU2019323697B2 AU 2019323697 B2 AU2019323697 B2 AU 2019323697B2 AU 2019323697 A AU2019323697 A AU 2019323697A AU 2019323697 A AU2019323697 A AU 2019323697A AU 2019323697 B2 AU2019323697 B2 AU 2019323697B2
Authority
AU
Australia
Prior art keywords
kbp
nmol
vehicle
calcitonin
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019323697A
Other languages
English (en)
Other versions
AU2019323697A1 (en
Inventor
Kim V ANDREASSEN
Kim Henriksen
Morten Asser Karsdal
Nina SONNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keybioscience Sa
Original Assignee
Keybioscience Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Sa filed Critical Keybioscience Sa
Publication of AU2019323697A1 publication Critical patent/AU2019323697A1/en
Assigned to KeyBioscience SA reassignment KeyBioscience SA Amend patent request/document other than specification (104) Assignors: KEY BIOSCIENCE AG
Priority to AU2025205152A priority Critical patent/AU2025205152A1/en
Application granted granted Critical
Publication of AU2019323697B2 publication Critical patent/AU2019323697B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
AU2019323697A 2018-08-22 2019-08-22 Acylated calcitonin mimetics Active AU2019323697B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205152A AU2025205152A1 (en) 2018-08-22 2025-07-04 Acylated calcitonin mimetics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1813678.8 2018-08-22
GBGB1813678.8A GB201813678D0 (en) 2018-08-22 2018-08-22 Acylated calcitonin mimetics
PCT/EP2019/072533 WO2020039051A1 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205152A Division AU2025205152A1 (en) 2018-08-22 2025-07-04 Acylated calcitonin mimetics

Publications (2)

Publication Number Publication Date
AU2019323697A1 AU2019323697A1 (en) 2021-03-04
AU2019323697B2 true AU2019323697B2 (en) 2025-08-07

Family

ID=63668212

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019323697A Active AU2019323697B2 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
AU2025205152A Pending AU2025205152A1 (en) 2018-08-22 2025-07-04 Acylated calcitonin mimetics

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205152A Pending AU2025205152A1 (en) 2018-08-22 2025-07-04 Acylated calcitonin mimetics

Country Status (18)

Country Link
US (1) US20220380432A1 (enExample)
EP (1) EP3840774A1 (enExample)
JP (2) JP2021535119A (enExample)
KR (2) KR102866729B1 (enExample)
CN (3) CN112601542A (enExample)
AU (2) AU2019323697B2 (enExample)
BR (1) BR112021003088A2 (enExample)
CA (1) CA3110033A1 (enExample)
CL (1) CL2021000427A1 (enExample)
CO (1) CO2021002071A2 (enExample)
EA (1) EA202190477A1 (enExample)
GB (1) GB201813678D0 (enExample)
IL (1) IL280885B2 (enExample)
MX (1) MX2021002072A (enExample)
PE (1) PE20211785A1 (enExample)
PH (1) PH12021550331A1 (enExample)
WO (1) WO2020039051A1 (enExample)
ZA (1) ZA202100869B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118684757A (zh) * 2023-03-24 2024-09-24 成都奥达生物科技有限公司 一种长效降钙素类似物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016110525A1 (en) * 2015-01-08 2016-07-14 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3095484A1 (en) * 2011-11-02 2016-11-23 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2005004792A2 (en) * 2003-06-24 2005-01-20 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2665464T3 (es) 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
ES2398237T3 (es) 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EP1834635B1 (en) 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Stable nanocapsule systems for the administration of active molecules
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CA2755068C (en) * 2009-03-12 2018-11-06 Keybioscience Ag Treatment of diabetes and metabolic syndrome
EP2493919A1 (en) * 2009-10-30 2012-09-05 Novo Nordisk A/S Derivatives of cgrp
JP6039569B2 (ja) * 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
US9006172B2 (en) * 2011-11-02 2015-04-14 Keybioscience Ag Peptide analogs for treating diseases and disorders
CN105722854B (zh) 2013-11-14 2020-08-04 关键生物科学有限公司 用于治疗疾病和病症的降钙素模拟物
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
JP2019517523A (ja) * 2016-06-03 2019-06-24 ケモセントリックス， インコーポレイテッド 肝線維症を治療する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095484A1 (en) * 2011-11-02 2016-11-23 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
WO2016110525A1 (en) * 2015-01-08 2016-07-14 Keybioscience Ag Calcitonin analogues for treating diseases and disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOFIE TRIER ET AL: "Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS., vol. 96, 1 October 2015, pages 329 - 337, *

Also Published As

Publication number Publication date
WO2020039051A1 (en) 2020-02-27
AU2019323697A1 (en) 2021-03-04
ZA202100869B (en) 2022-09-28
CL2021000427A1 (es) 2021-08-20
CN121021664A (zh) 2025-11-28
IL280885B1 (en) 2024-07-01
KR20250143876A (ko) 2025-10-02
CA3110033A1 (en) 2020-02-27
CN121226531A (zh) 2025-12-30
GB201813678D0 (en) 2018-10-03
PE20211785A1 (es) 2021-09-09
EA202190477A1 (ru) 2021-06-04
CN112601542A (zh) 2021-04-02
IL280885B2 (en) 2024-11-01
PH12021550331A1 (en) 2021-10-04
AU2025205152A1 (en) 2025-07-24
BR112021003088A2 (pt) 2021-05-11
IL280885A (en) 2021-04-29
KR102866729B1 (ko) 2025-10-02
JP2025023996A (ja) 2025-02-19
US20220380432A1 (en) 2022-12-01
JP2021535119A (ja) 2021-12-16
MX2021002072A (es) 2021-04-28
CO2021002071A2 (es) 2021-03-08
EP3840774A1 (en) 2021-06-30
KR20210047322A (ko) 2021-04-29

Similar Documents

Publication Publication Date Title
AU2019323697B2 (en) Acylated calcitonin mimetics
AU2014350328B2 (en) Calcitonin mimetics for treating diseases and disorders
AU2016247189B2 (en) Peptide analogs for treating diseases and disorders
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US20200199190A1 (en) Calcitonin Mimetics for Treating Diseases and Disorders
DK2773365T3 (en) Peptide FOR THE TREATMENT OF DISEASES AND DISORDERS
OA20012A (en) Acylated Calcitonin Mimetics.
WO2020039052A1 (en) Calcitonin mimetics for treating diseases and disorders
EA050377B1 (ru) Ацилированные миметики кальцитонина
BR122025024996A2 (pt) Miméticos de calcitonina acilados
HK1247623B (en) Calcitonin mimetics for treating diseases and disorders
HK1227415B (en) Calcitonin mimetics for treating diseases and disorders
HK1227415A1 (en) Calcitonin mimetics for treating diseases and disorders

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: KEYBIOSCIENCE SA

Free format text: FORMER NAME(S): KEY BIOSCIENCE AG

FGA Letters patent sealed or granted (standard patent)